Comparison of Antiretroviral Regimens: Adverse Effects and Tolerability Failure that Cause Regimen Switching
1
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background: The efficacy of antiretroviral therapy (ART) has improved, and the adverse effects of antiretroviral drugs have been reduced. However, these adverse effects still significantly influence patient compliance, increasing the risk of tolerability failure. Therefore, we investigated the adverse effects and tolerability failure causing changes in the first ART regimen, and identified the regimens that were most vulnerable to switching. Materials and Methods: We enrolled patients with human immunodeficiency virus (HIV) who commenced their first ART between January 1, 2011 and July 30, 2014. Patients who started their first ART regimen at the Kyungpook National University Hospital were included in the study if they were aged ≥18 years and were followed-up for ≥12 weeks. The primary dependent variable was the duration of treatment on the same ART regimen. We analyzed the maintenance rate of the first ART regimen based on the treatment duration between these groups using survival analysis and log rank test. The frequency of the adverse effects of ART regimens was analyzed by multiple response data analysis. Results: During the investigation period, 137 patients were enrolled. Eighty-one patients were maintained on the initial treatment regimen (59.1%). In protease inhibitor (PI)-based regimen group, 54 patients were maintained on the initial treatment regimen (54/98, 55.1%). In non-nucleoside reverse transcriptase inhibitor (NNRTI)-and integrase inhibitor (II)-based regimen group, 15 (15/26, 57.7%) and 12 (12/13, 92.3%) patients were maintained on the initial treatment regimen, respectively. Adverse effects that induced ART switching included rash (16/35, 45.7%), gastrointestinal discomfort or pain (7/35, 20%), diarrhea (7/35, 20%), hyperbilirubinemia (6/35, 17.1%), headache or dizziness (3/35, 8.5%). Among the treatment regimens, the group receiving an II-based regimen showed the least switching. The group receiving PI-and NNRTI-based regimens were most likely to switch due to adverse effects during the early treatment period. However, after about 18 months, switching was rarely observed in these groups. Among the PI drugs, darunavir/ ritonavir showed fewer drug changes than atazanavir/ritonavir (P = 0.004, log rank test) and lopinavir/ritonavir (P = 0.010). Among the NNRTI drugs, rilpivirne produced less switching than efavirenz (P = 0.045). Conclusion: Adverse effects to ART resulted in about a quarter of patients switching drugs during the early treatment period. II-based regimens were advantageous because they were less likely to induce switching within 18 months of treatment commencement. These findings indicated the importance of considering and monitoring the adverse effects of ART in order to improve adherence.
Abstract
Background: The efficacy of antiretroviral therapy (ART) has improved, and the adverse effects of antiretroviral drugs have been reduced. However, these adverse effects still significantly influence patient compliance, increasing the risk of tolerability failure. Therefore, we investigated the adverse effects and tolerability failure causing changes in the first ART regimen, and identified the regimens that were most vulnerable to switching. Materials and Methods: We enrolled patients with human immunodeficiency virus (HIV) who commenced their first ART between January 1, 2011 and July 30, 2014. Patients who started their first ART regimen at the Kyungpook National University Hospital were included in the study if they were aged ≥18 years and were followed-up for ≥12 weeks. The primary dependent variable was the duration of treatment on the same ART regimen. We analyzed the maintenance rate of the first ART regimen based on the treatment duration between these groups using survival analysis and log rank test. The frequency of the adverse effects of ART regimens was analyzed by multiple response data analysis. Results: During the investigation period, 137 patients were enrolled. Eighty-one patients were maintained on the initial treatment regimen (59.1%). In protease inhibitor (PI)-based regimen group, 54 patients were maintained on the initial treatment regimen (54/98, 55.1%). In non-nucleoside reverse transcriptase inhibitor (NNRTI)-and integrase inhibitor (II)-based regimen group, 15 (15/26, 57.7%) and 12 (12/13, 92.3%) patients were maintained on the initial treatment regimen, respectively. Adverse effects that induced ART switching included rash (16/35, 45.7%), gastrointestinal discomfort or pain (7/35, 20%), diarrhea (7/35, 20%), hyperbilirubinemia (6/35, 17.1%), headache or dizziness (3/35, 8.5%). Among the treatment regimens, the group receiving an II-based regimen showed the least switching. The group receiving PI-and NNRTI-based regimens were most likely to switch due to adverse effects during the early treatment period. However, after about 18 months, switching was rarely observed in these groups. Among the PI drugs, darunavir/ ritonavir showed fewer drug changes than atazanavir/ritonavir (P = 0.004, log rank test) and lopinavir/ritonavir (P = 0.010). Among the NNRTI drugs, rilpivirne produced less switching than efavirenz (P = 0.045). Conclusion: Adverse effects to ART resulted in about a quarter of patients switching drugs during the early treatment period. II-based regimens were advantageous because they were less likely to induce switching within 18 months of treatment commencement. These findings indicated the importance of considering and monitoring the adverse effects of ART in order to improve adherence.
참고문헌 (29)
- Mocroft A, "an observational study", Lancet, 362, pp.22~29 (2003)
- Brady MT, "Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era", J Acquir Immune Defic Syndr, 53, pp.86~94 (2010)
- Max B, "Management of the adverse effects of antiretroviral therapy and medication adherence", Clin Infect Dis, 30(Suppl 2), pp.S96~S116 (2000)
- Bangsberg DR, "Non-adherence to highly active antiretroviral therapy predicts progression to AIDS", AIDS, 15, pp.1181~1183 (2001)
- Nachega JB, "Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes", Ann Intern Med, 146, pp.564~573 (2007)
- 대한에이즈학회, "국내 HIV 감염인의 HIV", AIDS 진단 및 치료에 관한 임상진료지침 권고안, 2011, pp.43(2), 89~128[DOI]
- Chesney MA, "Factors affecting adherence to antiretroviral therapy", Clin Infect Dis, 30(Suppl 2), pp.S171~S176 (2000)
- Lennox JL, "Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1:a randomized, controlled equivalence trial", Ann Intern Med, 161, pp.461~471 (2014)
- Dennis L. Kasper, "Harrison's Principles of Internal Medicine" (2015), McGraw-Hill Education
- Thurairajah PH, "Incidence and characterization of serum transaminases elevations in pegylated interferon and ribavirin treated patients with chronic hepatitis C", Aliment Pharmacol Ther, 25, pp.1293~1300 (2007)
- Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, "National Institute of Allergy and Infectious Diseases", National Institute of Allergy and Infectious Diseases, ~ (2004)
- Group AIDSCT, "Table of Grading Severity of Adult Adverse Experiences", US Division of AIDS, National Institute of Allergy and Infectious Disease, ~ (1996)
- American Diabetes Association, "Standards of medical care in diabetes-2015 abridged for primary care providers", Clin Diabetes, 33, pp.97~111 (2015)
- Hawkins T, "Understanding and managing the adverse effects of antiretroviral therapy", Antiviral Res, 85, pp.201~209 (2010)
- Palella FJ Jr, "Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators", N Engl J Med, 338, pp.853~860 (1998)
- Mocroft A, "Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre", AIDS, 15, pp.185~194 (2001)
- Mocroft A, "Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient", physician choice in patients with hepatitis C coinfection, 2005, pp.21, 743~752
- Cicconi P, "Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral- naïve patients", HIV Med, 11, pp.104~113 (2010)
- d'Arminio Monforte A, "Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients", AIDS, 14, pp.499~507 (2000)
- Al-Dakkak I, "The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis", AIDS Care, 25, pp.400~414 (2013)
- O'Brien ME, "Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort", J Acquir Immune Defic Syndr, 34, pp.407~414 (2003)
- Orkin C, "Final 192-week efficacy and safety of once-daily darunavir", ritonavir compared with lopinavir, HIV Med, pp.2013, 14[DOI]
- Molina JM, "Once-daily atazanavir", ritonavir compared with twice-daily lopinavir, J Acquir Immune Defic Syndr, pp.2010, 53[DOI]
- Molina JM, "Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3randomised double-blind active-controlled trial", Lancet, 378, pp.238~246 (2011)
- Cohen CJ, "Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial", Lancet, 378, pp.229~237 (2011)
- Lennox JL, "Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection:a multicentre, double-blind randomised controlled trial", Lancet, 374, pp.796~806 (2009)
- Carr A, "Adverse effects of antiretroviral therapy", Lancet, 356, pp.1423~1430 (2000)
- Rockstroh JK, "Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir", emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK, 2013, pp.63, 77~85
- Nishijima T, "Once-daily darunavir", ritonavir and abacavir, emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies, pp.ml, AIDS[DOI]